Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of oral ETX0282 Administered in Healthy Subjects

Trial Profile

A Phase 1, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of oral ETX0282 Administered in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2018

At a glance

  • Drugs Cefpodoxime/ETX 0282 (Primary) ; Cefpodoxime proxetil
  • Indications Gram-negative infections; Urinary tract infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Entasis Therapeutics
  • Most Recent Events

    • 21 May 2018 According to an Entasis Therapeutics media release, the trial is expected to be completed in the first half of 2019.
    • 12 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top